Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology
+$0.04 today
- Market cap
- $3.10B
- Beta
- 0.90
- P/E (TTM)
- 98.7
- EPS (TTM)
- $0.07
Volume 2.76M
Average 1.66M
XERS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Xeris Biopharma Holdings, Inc.NASDAQ: XERS
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation dips below year-ago levels
Q1 FY2026 stock-based compensation of $4.14M fell 6.8% year over year, behind the +15.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 21.5% from the prior quarter. Over 3 fiscal years it compounded at +22.5% a year.
Context
- Stock-based compensation amounted to 7.7% of revenue in FY2025, down 1.4 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -6.8% toward the trailing-twelve-month pace of +15.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 22.37M USD
- Year-over-year change
- +21.8%
- 4-year CAGR
- +18.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.37M | +21.8% |
| FY2024 | 2024-12-31 | 18.36M | +71.4% |
| FY2023 | 2023-12-31 | 10.72M | -11.9% |
| FY2022 | 2022-12-31 | 12.16M | +6.8% |
| FY2021 | 2021-12-31 | 11.38M | — |
Stock-Based Compensation vs competitors
How XERS compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.9% is the 4th highest of 9, against a peer median of -34.4%.
- Stock-based compensation amounts to 7.0% of revenue for XERS, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $41.75M USD | +456.0% | +204.9% | — |
| LTM Mar 2026 | $22.06M USD | +15.9% | +22.5% | 7.0% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $19.67M USD | +177.6% | +77.3% | 20.4% |
| LTM Mar 2026 | $14.49M USD | -36.6% | — | 4.0% | |
| LTM Jun 2026 | $11.27M USD | -119.6% | +25.8% | 1.4% | |
| LTM Mar 2026 | $5.83M USD | +64.5% | +9.3% | 6.7% | |
| LTM Mar 2026 | $2.72M USD | -37.2% | -10.8% | — | |
| LTM Mar 2026 | $1.88M USD | -32.3% | — | — | |
| LTM Sep 2026 | €0 EUR | -100.0% | — | 0.0% | |
| Peer median (excluding XERS) | — | -34.4% | +25.8% | 4.0% | |
Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (122.73M) | (94.66M) | (62.26M) | (54.84M) | 554K |
| Depreciation & Amortization | 1.88M | 12.67M | 13.16M | 12.63M | 12.16M |
| Deferred Income Tax | (1.42M) | (1.42M) | (1.25M) | (2.27M) | 0 |
| Stock-Based Compensation | 11.38M | 12.16M | 10.72M | 18.36M | 22.37M |
| Change in Working Capital | 11.85M | (35.15M) | (6.29M) | (8.82M) | (10.36M) |
| Accounts Receivables | (13.37M) | (13.37M) | (8.37M) | (1.22M) | (10.64M) |
| Inventory | (7.47M) | (7.47M) | (14.8M) | (8.78M) | (19.29M) |
| Accounts Payables | (4.32M) | (4.32M) | 6.96M | (9.61M) | (69K) |
| Other Working Capital | 19.98M | (9.99M) | 9.92M | 10.79M | 19.63M |
| Other Non-Cash Items | 3.5M | 3.52M | (1.1M) | (2.05M) | 3.91M |
| Operating Cash Flow | (102.89M) | (102.89M) | (47.02M) | (36.98M) | 28.63M |
| Capital Expenditures | (524K) | (524K) | (2.26M) | (868K) | (696K) |
| Acquisitions (Net) | 38.47M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (43.02M) | 0 | (43.74M) | (34.49M) | 0 |
| Sales of Investments | 34.99M | 34.99M | 40M | 40.24M | 0 |
| Other Investing Activities | 4.55M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 34.46M | 34.46M | (6M) | 4.88M | (696K) |
| Debt Repayment | 0 | 102.72M | 0 | 38.17M | 9.17M |
| Common Stock Issued | 27M | 30M | 581K | 0 | 13.1M |
| Common Stock Repurchased | (534K) | (468K) | (1.01M) | (3.73M) | (10.88M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (4.78M) | (604K) | 1.73M | 0 |
| Financing Cash Flow | 27.25M | 127.47M | (1.61M) | 36.17M | 11.39M |
| Effect of Forex Changes | (3K) | (4.35M) | 0 | 0 | 0 |
| Net Change in Cash | 59.04M | 59.04M | (54.64M) | 4.07M | 39.32M |
| Free Cash Flow | (103.42M) | (103.42M) | (49.29M) | (37.85M) | 27.93M |
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
Intrinsic Alpha fair value
Locked
Current Price
$16.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.